Fate Therapeutics (FATE) Misses Q3 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Paradium AI (PAAI) Halted, News Pending
- Shipping stocks on fire — but cracks are forming in the rate rally
- BofA Securities Reiterates Buy Rating on Apple (AAPL)
Fate Therapeutics Reports Third Quarter 2018 Financial Results and Highlights Operational Progress
November 1, 2018 4:01 PM EDTTwenty Subjects Treated across Three Phase 1 Studies of FATE-NK100
Entered into Off-the-Shelf, iPSC-derived CAR-T Cell Collaboration with ONO Pharmaceutical
Completed $144M Common Stock Public Offering
Three Oral and Four Poster Presentations Covering Product Pipeline will be Presented at ASH Annual Meeting
SAN DIEGO, Nov. 01, 2018 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today reported business... More
